Noveris Health SciencesMYCOF 23 Gross Margin % is 0.00% as of Mar. 2026. GuruFocus rates MYCOF with a GF Score™ of 23/100. Among 935 Drug Manufacturers companies, Noveris Health Sciences ranks worse than 106951.76% on this metric.
MYCOF's Gross Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 48.54 * Ranked among companies with meaningful Gross Margin % only.
Noveris Health Sciences had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Noveris Health Sciences was 0.00% per year.
Noveris Health Sciences (OTCPK:MYCOF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Noveris Health Sciences had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Noveris Health Sciences Gross Margin % Related Terms
Noveris Health Sciences Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Noveris Health Sciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noveris Health Sciences Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Noveris Health Sciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Noveris Health Sciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Noveris Health Sciences (MYCOF) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Noveris Health Sciences and its competitors. Over the past decade, Noveris Health Sciences' Gross Margin % has ranged from 25.40 to 47.12. According to the industry distribution chart, Noveris Health Sciences ranks #999999 out of 935 companies in the Drug Manufacturers industry.
Is Noveris Health Sciences' Gross Margin % too high?
Noveris Health Sciences' current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 25.40 to a high of 47.12. Based on the distribution chart, Noveris Health Sciences ranks #999999 out of 935 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Noveris Health Sciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Noveris Health Sciences ranks #999999 out of 935 companies for Gross Margin %. This places Noveris Health Sciences in the lower half of its industry. The industry median Gross Margin % is 48.54. Historically, Noveris Health Sciences' own Gross Margin % has ranged from 25.40 to 47.12 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Noveris Health Sciences and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noveris Health Sciences's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Noveris Health Sciences (MYCOF) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Noveris Health Sciences' overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
23GF Score
Get the complete analysis for MYCOF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYCOF has been successfully added to your 
